The mitochondrial cascade hypothesis for parkinson's disease

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3390-3397

  Cardoso, Sandra M ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Autophagy; Intracellular traffic; Lysosomal function; Mitochondria; Mitochondrial biogenesis; Mitochondrial dna; Oxidative stress; Protein oligomerization

Indexed keywords

ALPHA SYNUCLEIN; CALPAIN; GLUCOSYLCERAMIDASE; GUANOSINE TRIPHOSPHATE; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TOXIN; UBIQUITIN C;

ARTICLE; BIOGENESIS; CELL DEGENERATION; CELL FUNCTION; DOPAMINERGIC NERVE CELL; HUMAN; LEWY BODY; MICROTUBULE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NERVE CELL NECROSIS; OLIGOMERIZATION; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REACTOR CASCADE;

CENTRAL NERVOUS SYSTEM AGENTS; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION; HUMANS; MITOCHONDRIA; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 80055076405     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072508     Document Type: Article

References (93)

1. Cardoso SM, Moreira PI, Agostinho P, Pereira C, Oliveira CR. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Curr Drug Targets CNS Neurol Disord 2005; 4(4): 405-19.
2. Arduíno DM, Esteves AR, Oliveira CR, Cardoso SM. Mitochon-drial metabolism modulation: a new therapeutic approach for Park-inson's disease. CNS Neurol Disord Drug Targets 201; 9(1): 105-119.
3. Ahlqvist G, Landin S, Wroblewski R. Ultrastructure of skeletal muscle in patients with Parkinson's disease and upper motor le-sions. Lab Invest 1975; 32(5): 673-9.
4. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Sci-ence 1983; 219(4587): 979-80.
5. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1(8649): 1269.
6. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD Jr, Turn-bull DM. Mitochondrial function in Parkinson's disease. Lancet 1989; 2(8653): 49.
7. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochon-drial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4(1): 27-34.
8. Barroso N, Campos Y, Huertas R, et al. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin Chem 1993; 39(4): 667-9.
9. Esteves AR, Arduino DM, Silva DFF, Martins Branco D, Oliveira CR, Cardoso SM Mitochondrial Metabolism in Age-related Neu-rodegenerative disorders: Alzheimer's and Parkinson's Revisited Mitochondria: Structure, Functions and Dysfunctions Editor: Oliver L. Svensson 2010
10. Parker WD Jr, Parks JK. Mitochondrial ND5 mutations in idio-pathic Parkinson's disease. Biochem Biophys Res Commun. 2005; 326(3): 667-9.
11. Winkler-Stuck K, Kirches E, Mawrin C, et al. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. J Neural Transm. 2005; 112(4): 499-518.
12. King MP, Attardi G. Human cells lacking mtDNA: repopulationwith exogenous mitochondria by complementation. Science 1989; 246: 500-3.
13. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, Tuttle JB. Altered calcium homeostasis in cells transformed by mi-tochondria from individuals with Parkinson's disease. J Neurochem 1997; 68: 1221-33.
14. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663-71.
15. Trimmer PA, Borland MK, Keeney PM, Bennett Jr JP, Parker Jr WD. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004; 88: 800-12.
16. Esteves AR, Domingues AF, Ferreira IL, et al. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 2008; 8: 219-28.
17. Esteves AR, Arduíno DM, Swerdlow RH, Oliveira CR, Cardoso SM. Dysfunctional mitochondria uphold calpain activation: contri-bution to Parkinson's disease pathology. Neurobiol Dis 2010; 37(3): 723-30.
18. Esteves AR, Arduíno DM, Swerdlow RH, Oliveira CR, Cardoso SM. Microtubule depolymerization potentiates alpha-synuclein oli-gomerization. Front Aging Neurosci 2010; 1: 5-10.
19. Swerdlow RH, Parks JK, Davis JN 2nd, et al. Matrilineal inheri-tance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 1998; 44(6): 873-81.
20. Ekstrand MI, Terzioglu M, Galter D, et al. Progressive parkin-sonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-30.
21. Liang CL, Wang TT, Luby-Phelps K, German DC. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implica-tions for Parkinson's disease. Exp Neurol 2007; 203: 370-80.
22. Swerdlow RH, Parker WD, Currie LJ, et al. Gender ratio differ-ences between Parkinson's disease patients and their affected rela-tives. Parkinsonism Relat Disord. 2001; 7(2): 129-33.
23. Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT. Mitochon-drial turnover and aging of long-lived postmitotic cells: the mito-chondrial-lysosomal axis theory of aging. Antioxid Redox Signal 2010; 12(4): 503-35.
24. Larsson NG. Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem. 2010; 79: 683-706.
25. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis. 2010; 2: S265-79.
26. Bender A, Krishnan KJ, Morris CM, et al. High levels of mito-chondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
27. Bender A, Schwarzkopf RM, McMillan A, et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA dele-tions. J Neurol 2008; 255(8): 1231-5.
28. Reeve AK, Krishnan KJ, Elson JL, et al. Nature of mitochondrial DNA deletions in substantia nigra neurons. Am J Hum Genet 2008; 82(1): 228-35.
29. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66(5): 646-61.
30. Arduíno DM, Esteves AR, Cardoso SM. Mitochondrial fu-sion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty. Parkinsons Dis. 2011; 2011: 767230.
31. Esteves AR, Arduíno DM, Silva DF, Oliveira CR, Cardoso SM. Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oli-gomerization in PD. Parkinsons Dis. 2011; 2011: 693761.
32. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009; 218(2): 235-46.
33. Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D. Mutant and wild-type alpha-synuclein interact with mitochondrial cyto-chrome C oxidase. J Mol Neurosci 2002; 18(3): 229-38.
34. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Ananda-theerthavarada, HK. Mitochondrial import and accumulation of al-pha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283(14): 9089-100.
35. Li WW, Yang R, Guo JC, et al. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 2007; 18(15): 1543-6.
36. Shavali S, Brown-Borg HM, Ebadi M, Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overex-pressing cells. Neurosci Lett 2008; 439(2): 125-8.
37. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008; 65(7-8): 1272-84.
38. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degen-eration and cell death. J Neurosci 2006; 26(1): 41-50.
39. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Bio-chemistry 1998; 37: 3358-68.
40. Branco DM, Arduino DM, Esteves AR, Silva DF, Cardoso SM, Oliveira CR. Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci 2010; 2:17.
41. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-9.
42. Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 2001; 35(6): 885-93.
43. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet. 2005 Jul 15; 14(14): 2063-73.
44. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochon-drial localization of DJ-1 leads to enhanced neuroprotection. J Neu-rosci Res 2009; 87(1): 123-9.
45. Hayashi T, Ishimori C, Takahashi-Niki K, et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Bio-phys Res Commun. 2009; 390(3): 667-72.
46. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12(2): 119-31.
47. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira A.H, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 2010; 19(24): 4861-70.
48. Narendra D, Tanaka A, Suen DF,Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183(5): 795-803.
49. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent re-cruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 2010; 107(1): 378-83.
50. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabi-lized on impaired mitochondria to activate Parkin. PLoS Biol 2010; 8(1): e1000298.
51. Alegre-Abarrategui J, Christian H, Lufino MM, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009; 18(21): 4022-34.
52. Bogaerts V, Nuytemans K, Reumers J, et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat. 2008; 29(6): 832-40.
53. Martins LM, Morrison A, Klupsch K, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol. 2004; 24(22): 9848-62.
54. Jones JM, Datta P, Srinivasula SM, et al. Loss of Omi mitochon-drial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003; 425(6959): 721-7.
55. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443(7113): 787-95.
56. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110(5): 517-36.
57. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004; 318(1): 121-34.
58. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-73.
59. Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci 2005; 118: 5411-9.
60. Pham NA, Richardson T, Cameron J, Chue B, Robinson BH. Altered mitochondrial structure and motion dynamics in living cells with energy metabolism defects revealed by real time microscope imaging. Microsc Microanal 2004; 10: 247-60.
61. Kim-Han JS, Antenor-Dorsey JA, O'Malley KL. The Parkinsonian Mimetic, MPP+, Specifically Impairs Mitochondrial Transport in Dopamine Axons. J Neurosci 2011; 31(19): 7212-21.
62. Borland MK, Trimmer PA, Rubinstein JD, et al. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkin-son's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener 2008; 29: 3-21.
63. Cappelletti G. Surrey T, Maci R. The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a de-stabilising factor. FEBS Lett 2005; 579: 4781-6.
64. Ren Y, Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem 2007; 103: 303-11.
65. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR, Cardoso SM. Oxidative Stress involvement in alpha-synuclein oligomeriza-tion in Parkinsons disease cybrids. Antioxid Redox Signal 2009; 11: 439-48.
66. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synu-cleinopathy lesions. Science 2000; 290(5493): 985-9.
67. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regu-lates ubiquitination and compromises parkin's protective function. Science 2004; 304(5675): 1328-31.
68. Yao D, Gu Z, Nakamura T, et al. Nitrosative stress linked to spo-radic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 2004; 101(29): 10810-4.
69. Leong SL, Pham CL, Galatis D, et al. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med 2009; 46(10), 1328-37.
70. Soong NW, Hinton DR, Cortopassi G, Arnheim N. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 1992; 2: 318-23.
71. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histo-pathol 1997; 12: 25-31.
72. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and mac-roautophagy in neuronal cells. J Biol Chem 2008; 283: 23542-56.
73. Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 2002; 33(5): 611-9.
74. Gray DA, Woulfe J. Lipofuscin and ageing: a matter of toxic waste. Sci Ageing Knowledge Environ. 2005; 5: re1.
75. Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Park-inson disease and Gaucher disease. Hum Mol Genet 2010; 19(19): 3771-81.
76. Sidransky E, Samaddar T, Tayebi N. Mutations in GBA are associ-ated with familial Parkinson disease susceptibility and age at onset. Neurology 2009; 73(17): 1424-5.
77. Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009; 30(9): 1515-7.
78. Yoon Y, McNiven MA. Mitochondrial division: New partners in membrane pinching. Curr Biol 2001; 11(2): R67-70.
79. Terman A, Dalen H, Eaton JW, Neuzil J, Brunk UT. Mitochondrial recycling and ageing of cardiac myocytes: the role of autophagocy-tosis. Exp Gerontol 2003; 38(8): 863-76.
80. Baricault L, Segui B, Guegand L, et al. OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals. Exp Cell Res 2007; 313: 3800-8.
81. Duvezin-Caubet S, Jagasia R, Wagener J, et al. Proteolytic process-ing of OPA1 links mitochondrial dysfunction to alterations in mito-chondrial morphology. J Biol Chem 2006; 281: 37972-9.
82. Jahani-Asl A, Pilon-Larose K, Xu W, et al. The mitochondrial inner membrane GTPase, Optic Atrophy 1 (Opa1), restores mito-chondrial morphology and promotes neuronal survival following excitotoxicity. J Biol Chem 2011; 286(6): 4772-82.
83. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006; 17(5-6): 431-9.
84. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2000; 97(10): 5440-4.
85. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkin-son disease. J Clin Invest 2003; 112(6): 892-901.
86. Armstrong JS, Mitochondria-directed therapeutics. Antioxid Redox Signal 2008; 10(3): 575-8.
87. Ghosh S, George S, Roy U, Ramachandran D, Kolthur-Seetharam U. NAD: a master regulator of transcription. Biochim Biophys Acta 2010; 1799(10-12): 681-93.
88. Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-21.
89. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11(2): 437-44.
90. Magni G, G Orsomando, N Raffelli, S Ruggieri, Enzymology of mammalian NAD metabolism in health and disease. Front. Biosci 2008; 13: 6135-54.
91. Ahn BH, Kim HS, Song S, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105(38): 14447-52
92. Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J Biol Chem 2006; 281: 14250-5.
93. Esteves AR, Lu J, Rodova M, et al. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkin-son's subject mitochondrial transfer. J Neurochem 2010; 113(3): 674-82.